Global /Japan /Healthcare /Biotechnology /4584

Kidswell Bio Corp.

4584

• TSE: 4584 • Delayed

221JPY -3.1%

1.38 USD

As of 5 June 2026, Kidswell Bio Corp. has a market cap of $70.69M USD, ranking #28053 globally and #2530 in Japan. It ranks #2534 in the Healthcare sector, and #488 in the Biotechnology industry.

Global Rank

28053

Country Rank

2530

Sector Rank

2534

Industry Rank

488

Key Stats

Market Cap

$70.69MUSD

11.31B JPY

Enterprise Value

$63.44MUSD

10.15B JPY

Revenue (TTM)

$44.15MUSD

7.06B JPY

Net Income (TTM)

$149.8KUSD

23.97M JPY

PE Ratio

471.9

Forward PE

13.4

PS Ratio

1.6

PB Ratio

5.9

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Shinya Kurebayashi open_in_new

Employees

Founded

2001

Website

kidswellbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.1%	-8.4%	-9.2%	-18%	-8.8%	12%	74%	-3.4%	-50%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4584 キッズウェル・バイオ株式会社 ISIN: JP3386460004 Shares Out.: Shares Outstanding: 49.623M¹ Shares Float: 35.745M² TV: TradingView: TSE: 4584 SA: Stock Analysis: TYO: 4584 YF: Yahoo Finance: 4584.T GF: Google Finance: TYO: 4584 BA: Barron's: 4584 MS: Morningstar: XTKS: 4584	221 JPY	TV: TradingView: TSE: 4584 SA: Stock Analysis: TYO: 4584 YF: Yahoo Finance: 4584.T GF: Google Finance: TYO: 4584 BA: Barron's: 4584 MS: Morningstar: XTKS: 4584

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Kidswell Bio Corp.

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 1K%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 1K%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 645%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 395%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 140%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 61%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 258K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 226K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 68K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 63K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 61K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 60K%	37.2	Switzerland

chevron_leftBack